In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
|Articles|April 25, 2023
Supplements and Featured Publications
- Addressing Unmet Needs in Chronic Phase CML With Third-Generation TKI
Addressing Unmet Needs in Chronic Phase CML With Third-Generation TKI
Advertisement
This publication is sponsored by Takeda Pharmaceuticals U.S.A., Inc.
This clinical brief provides key information on third-generation tyrosine kinase inhibitor for patients with chronic phase chronic myeloid leukemia (CP-CML). Interviews with Roy Beveridge, MD, and Paul B. Koller, MD, offer insights on the management of CP-CML from the payer and clinical perspectives.
Advertisement
Related to this article
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5